These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer's disease (DELCODE). Jessen F; Spottke A; Boecker H; Brosseron F; Buerger K; Catak C; Fliessbach K; Franke C; Fuentes M; Heneka MT; Janowitz D; Kilimann I; Laske C; Menne F; Nestor P; Peters O; Priller J; Pross V; Ramirez A; Schneider A; Speck O; Spruth EJ; Teipel S; Vukovich R; Westerteicher C; Wiltfang J; Wolfsgruber S; Wagner M; Düzel E Alzheimers Res Ther; 2018 Feb; 10(1):15. PubMed ID: 29415768 [TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment. Wolfsgruber S; Polcher A; Koppara A; Kleineidam L; Frölich L; Peters O; Hüll M; Rüther E; Wiltfang J; Maier W; Kornhuber J; Lewczuk P; Jessen F; Wagner M J Alzheimers Dis; 2017; 58(3):939-950. PubMed ID: 28527210 [TBL] [Abstract][Full Text] [Related]
4. Prevalence of abnormal Alzheimer's disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples. Wolfsgruber S; Molinuevo JL; Wagner M; Teunissen CE; Rami L; Coll-Padrós N; Bouwman FH; Slot RER; Wesselman LMP; Peters O; Luther K; Buerger K; Priller J; Laske C; Teipel S; Spottke A; Heneka MT; Düzel E; Drzezga A; Wiltfang J; Sikkes SAM; van der Flier WM; Jessen F; Alzheimers Res Ther; 2019 Jan; 11(1):8. PubMed ID: 30654834 [TBL] [Abstract][Full Text] [Related]
5. Plasma neurofilament light chain as a biomarker of Alzheimer's disease in Subjective Cognitive Decline and Mild Cognitive Impairment. Giacomucci G; Mazzeo S; Bagnoli S; Ingannato A; Leccese D; Berti V; Padiglioni S; Galdo G; Ferrari C; Sorbi S; Bessi V; Nacmias B J Neurol; 2022 Aug; 269(8):4270-4280. PubMed ID: 35288777 [TBL] [Abstract][Full Text] [Related]
6. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study. Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097 [TBL] [Abstract][Full Text] [Related]
7. Discordant amyloid-β PET and CSF biomarkers and its clinical consequences. de Wilde A; Reimand J; Teunissen CE; Zwan M; Windhorst AD; Boellaard R; van der Flier WM; Scheltens P; van Berckel BNM; Bouwman F; Ossenkoppele R Alzheimers Res Ther; 2019 Sep; 11(1):78. PubMed ID: 31511058 [TBL] [Abstract][Full Text] [Related]
8. Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans. Moon S; Kim S; Mankhong S; Choi SH; Vandijck M; Kostanjevecki V; Jeong JH; Yoon SJ; Park KW; Kim EJ; Yoon B; Kim HJ; Jang JW; Hong JY; Park DH; Shaw LM; Kang JH Alzheimers Res Ther; 2021 Jan; 13(1):22. PubMed ID: 33436035 [TBL] [Abstract][Full Text] [Related]
9. Biomarkers in subtypes of mild cognitive impairment and subjective cognitive decline. Eliassen CF; Reinvang I; Selnes P; Grambaite R; Fladby T; Hessen E Brain Behav; 2017 Sep; 7(9):e00776. PubMed ID: 28948074 [TBL] [Abstract][Full Text] [Related]
10. Progression of Subjective Cognitive Decline to MCI or Dementia in Relation to Biomarkers for Alzheimer Disease: A Meta-analysis. Rostamzadeh A; Bohr L; Wagner M; Baethge C; Jessen F Neurology; 2022 Oct; 99(17):e1866-e1874. PubMed ID: 36028322 [TBL] [Abstract][Full Text] [Related]
11. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia. Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593 [TBL] [Abstract][Full Text] [Related]
12. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort. Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN; Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591 [TBL] [Abstract][Full Text] [Related]
13. Subjective cognitive decline is related to CSF biomarkers of AD in patients with MCI. Wolfsgruber S; Jessen F; Koppara A; Kleineidam L; Schmidtke K; Frölich L; Kurz A; Schulz S; Hampel H; Heuser I; Peters O; Reischies FM; Jahn H; Luckhaus C; Hüll M; Gertz HJ; Schröder J; Pantel J; Rienhoff O; Rüther E; Henn F; Wiltfang J; Maier W; Kornhuber J; Wagner M Neurology; 2015 Mar; 84(12):1261-8. PubMed ID: 25716354 [TBL] [Abstract][Full Text] [Related]
14. Association of Subjective Cognitive Decline with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Pathology in Cognitively Intact Older Adults: The CABLE Study. Wen C; Bi YL; Hu H; Huang SY; Ma YH; Hu HY; Tan L; Yu JT J Alzheimers Dis; 2022; 85(3):1143-1151. PubMed ID: 34924386 [TBL] [Abstract][Full Text] [Related]
15. Which features of subjective cognitive decline are related to amyloid pathology? Findings from the DELCODE study. Miebach L; Wolfsgruber S; Polcher A; Peters O; Menne F; Luther K; Incesoy E; Priller J; Spruth E; Altenstein S; Buerger K; Catak C; Janowitz D; Perneczky R; Utecht J; Laske C; Buchmann M; Schneider A; Fliessbach K; Kalbhen P; Heneka MT; Brosseron F; Spottke A; Roy N; Teipel SJ; Kilimann I; Wiltfang J; Bartels C; Düzel E; Dobisch L; Metzger C; Meiberth D; Ramirez A; Jessen F; Wagner M Alzheimers Res Ther; 2019 Jul; 11(1):66. PubMed ID: 31366409 [TBL] [Abstract][Full Text] [Related]
16. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model. Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W; J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262 [TBL] [Abstract][Full Text] [Related]
17. Association of Neurogranin and BACE1 With Clinical Cognitive Decline in Individuals With Subjective Cognitive Decline. Wang X; Freiesleben SD; Schneider LS; Preis L; Priller J; Spruth EJ; Altenstein S; Schneider A; Fliessbach K; Wiltfang J; Hansen N; Jessen F; Rostamzadeh A; Duzel E; Glanz W; Incesoy EI; Buerger K; Janowitz D; Ewers M; Perneczky R; Rauchmann BS; Teipel SJ; Kilimann I; Goerss D; Laske C; Munk MHJ; Spottke A; Roy-Kluth N; Heneka MT; Brosseron F; Wagner M; Wolfsgruber S; Ramirez A; Kleineidam L; Stark M; Peters O Neurology; 2024 Oct; 103(8):e209806. PubMed ID: 39303184 [TBL] [Abstract][Full Text] [Related]